Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters
Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and a...
Saved in:
Published in | Menopause (New York, N.Y.) Vol. 18; no. 11; p. 1198 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.11.2011
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and anthropometric and metabolic parameters.
In a case-control study, we studied 102 postmenopausal women with pathologically confirmed, incident invasive breast cancer and 102 control women matched on age and time of diagnosis between 2003 and 2010 at Army Share Fund Hospital, Veterans' Hospital (NIMTS). Levels of serum visfatin, adiponectin, leptin, metabolic parameters, carcinoembryonic antigen, and CA 15-3 were determined.
The mean serum visfatin level was significantly higher in case than in control participants (P < 0.001). Women in the highest quartile of visfatin concentration presented significantly higher odds for PBC, adjusting for age, date of diagnosis, education, body mass index, waist circumference, years with menstruation, parity/age at first full-term pregnancy, breast-feeding, family history of cancer, use of exogenous hormones, alcohol consumption, smoking status, homeostasis model assessment score, and serum leptin and adiponectin concentrations (odds ratio, 7.93; 95% CI, 2.52-24.9). In case participants, the visfatin level correlated significantly with the tumor marker CA 15-3 (P = 0.03) but not with metabolic and anthropometric variables (P > 0.05).
Further prospective studies are needed to determine whether an elevated serum visfatin level is implicated in the etiopathogenesis of PBC or reflects changes during PBC progression and could therefore be used as a biomarker for PBC. |
---|---|
AbstractList | Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and anthropometric and metabolic parameters.
In a case-control study, we studied 102 postmenopausal women with pathologically confirmed, incident invasive breast cancer and 102 control women matched on age and time of diagnosis between 2003 and 2010 at Army Share Fund Hospital, Veterans' Hospital (NIMTS). Levels of serum visfatin, adiponectin, leptin, metabolic parameters, carcinoembryonic antigen, and CA 15-3 were determined.
The mean serum visfatin level was significantly higher in case than in control participants (P < 0.001). Women in the highest quartile of visfatin concentration presented significantly higher odds for PBC, adjusting for age, date of diagnosis, education, body mass index, waist circumference, years with menstruation, parity/age at first full-term pregnancy, breast-feeding, family history of cancer, use of exogenous hormones, alcohol consumption, smoking status, homeostasis model assessment score, and serum leptin and adiponectin concentrations (odds ratio, 7.93; 95% CI, 2.52-24.9). In case participants, the visfatin level correlated significantly with the tumor marker CA 15-3 (P = 0.03) but not with metabolic and anthropometric variables (P > 0.05).
Further prospective studies are needed to determine whether an elevated serum visfatin level is implicated in the etiopathogenesis of PBC or reflects changes during PBC progression and could therefore be used as a biomarker for PBC. |
Author | Lekka, Antigoni Papadavid, Evangelia Dalamaga, Maria Sotiropoulos, George Pelekanos, Nicolaos Karmaniolas, Konstantinos |
Author_xml | – sequence: 1 givenname: Maria surname: Dalamaga fullname: Dalamaga, Maria email: madalamaga@med.uoa.gr organization: Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Athens, Greece. madalamaga@med.uoa.gr – sequence: 2 givenname: Konstantinos surname: Karmaniolas fullname: Karmaniolas, Konstantinos – sequence: 3 givenname: Evangelia surname: Papadavid fullname: Papadavid, Evangelia – sequence: 4 givenname: Nicolaos surname: Pelekanos fullname: Pelekanos, Nicolaos – sequence: 5 givenname: George surname: Sotiropoulos fullname: Sotiropoulos, George – sequence: 6 givenname: Antigoni surname: Lekka fullname: Lekka, Antigoni |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21712732$$D View this record in MEDLINE/PubMed |
BookMark | eNo1UMtOHDEQtCKiLAv5gwj5AxjwY7yzc4wQJEhIuSRn1Pa0WScztuX2Eu138kM4SzhUV1dLXa2uNTuJKSJjX6S4kmIcrp8WvBJWSI1abpVEJb35wE6l0aITeuhXbE30WwihRjV8YislB6kGrU7Zy-2Mz1Bx4oRlv_DnQB5qiNcxuNQYljAhz7tEDSXYRIe5qwUieSxAyNs6zsShIAei5MLR7G-oO14C_eHJ85yoLhhThj3BzG1BoModRIeFhzhhxlZinQ_cl7RwmEJu_7l2_rL55yNDnBrqrqScFqwluOOotWDT3FSGAk1hoXP20cNM-Pk_n7Ffd7c_b753Dz--3d98feicNsZ0XjsPTgyw3QorN97YEUU_2sGIUantZpj6XqNTZjRSTOO_wDZWSts37gVodcYu3nzz3i44PeYSFiiHx_d01SvEE4Uf |
CitedBy_id | crossref_primary_10_18632_oncotarget_15080 crossref_primary_10_1111_bcpt_12623 crossref_primary_10_1186_s12964_024_01474_4 crossref_primary_10_3109_09513590_2014_975687 crossref_primary_10_3892_or_2015_4391 crossref_primary_10_1111_ajco_12090 crossref_primary_10_1111_obr_12377 crossref_primary_10_1371_journal_pone_0067349 crossref_primary_10_3389_fcell_2024_1408844 crossref_primary_10_1007_s12020_018_1550_3 crossref_primary_10_1021_jm4001049 crossref_primary_10_1016_j_lfs_2022_120706 crossref_primary_10_1016_j_peptides_2017_04_007 crossref_primary_10_1210_er_2011_1015 crossref_primary_10_1515_hmbci_2018_0079 crossref_primary_10_1016_j_maturitas_2011_12_013 crossref_primary_10_1371_journal_pone_0073183 crossref_primary_10_1016_j_metabol_2018_01_001 crossref_primary_10_1002_cbf_3279 crossref_primary_10_1097_MD_0000000000011345 crossref_primary_10_1016_j_ejphar_2016_08_029 crossref_primary_10_2217_bmm_13_99 crossref_primary_10_1016_j_alkona_2015_05_002 crossref_primary_10_1016_j_tjog_2015_05_001 crossref_primary_10_1016_j_mehy_2012_07_036 crossref_primary_10_1158_1055_9965_EPI_13_0258 crossref_primary_10_5314_wjd_v2_i4_27 crossref_primary_10_18632_oncotarget_17853 crossref_primary_10_1016_j_bbrc_2012_01_072 crossref_primary_10_18632_oncotarget_8615 crossref_primary_10_18632_oncotarget_8932 crossref_primary_10_1016_j_cyto_2019_03_002 crossref_primary_10_1097_GME_0b013e31827f06dc crossref_primary_10_6000_1929_2279_2015_04_01_3 crossref_primary_10_1016_j_lungcan_2018_10_010 crossref_primary_10_3390_biomedicines11020297 crossref_primary_10_1016_j_peptides_2013_11_010 crossref_primary_10_1016_j_canlet_2020_10_045 crossref_primary_10_1111_obr_13004 crossref_primary_10_1016_j_orcp_2015_08_017 crossref_primary_10_1111_bph_13505 crossref_primary_10_1016_j_jab_2014_08_003 crossref_primary_10_1186_1471_2407_13_54 crossref_primary_10_1007_s13679_019_00364_y crossref_primary_10_1016_j_ygyno_2013_02_022 crossref_primary_10_3390_cancers15051572 crossref_primary_10_1158_1078_0432_CCR_15_2704 crossref_primary_10_1515_hmbci_2015_0016 crossref_primary_10_1016_j_metabol_2022_155326 crossref_primary_10_1097_MD_0000000000014359 crossref_primary_10_1515_hmbci_2015_0018 crossref_primary_10_3389_fendo_2020_00066 crossref_primary_10_1016_j_clinbiochem_2013_01_001 crossref_primary_10_1016_j_ejphar_2019_03_016 crossref_primary_10_3934_molsci_2017_3_252 crossref_primary_10_1016_j_semcancer_2024_01_003 crossref_primary_10_1016_j_phrs_2016_10_027 crossref_primary_10_1155_2015_253519 crossref_primary_10_4236_jdm_2022_122011 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/gme.0b013e31821e21f5 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1530-0374 |
ExternalDocumentID | 21712732 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .GJ .XZ .Z2 0R~ 123 4Q1 4Q2 4Q3 53G 5RE 5VS AAAAV AAHPQ AAIQE AAJCS AAMTA AARTV AASCR AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFS ACILI ACWDW ACWRI ACWUS ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AFDTB AFEXH AHQNM AHVBC AINUH AJIOK AJNWD AJNYG AJZMW ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F5P FCALG FD6 FL- GMYUL GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 L-C NPM N~M O9- OAG OAH OCUKA ODA ODMTH OHYEH OJAPA OLG OLW OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWW OWX OWY OWZ OXXIT P-K PDI R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH ZFV ZZMQN |
ID | FETCH-LOGICAL-c3555-f3cfac07a880b16f5b9e049b750922867d443ec259510d912736b11b473640a32 |
IngestDate | Sat Sep 28 07:48:36 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3555-f3cfac07a880b16f5b9e049b750922867d443ec259510d912736b11b473640a32 |
PMID | 21712732 |
ParticipantIDs | pubmed_primary_21712732 |
PublicationCentury | 2000 |
PublicationDate | 2011-Nov |
PublicationDateYYYYMMDD | 2011-11-01 |
PublicationDate_xml | – month: 11 year: 2011 text: 2011-Nov |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Menopause (New York, N.Y.) |
PublicationTitleAlternate | Menopause |
PublicationYear | 2011 |
SSID | ssj0002927 |
Score | 2.3028412 |
Snippet | Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1198 |
SubjectTerms | Adiponectin - blood Aged Aged, 80 and over Biomarkers - blood Breast Neoplasms - blood Breast Neoplasms - etiology Carcinoembryonic Antigen - blood Case-Control Studies Cytokines - blood Female Humans Leptin - blood Logistic Models Middle Aged Mucin-1 - blood Nicotinamide Phosphoribosyltransferase - blood Obesity - blood Obesity - complications Odds Ratio Postmenopause - blood Risk |
Title | Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21712732 |
Volume | 18 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Za9tAEMeXuIVSKKVN74uB9s1R45V1WI-lTQgtDnlIIG9hd7XbmuowkW1Iv2a_UGd2tZacOvR4sCwkIwnPT7szw39mGXunhcy0iXkwyVSMAcokCcRY4x6-eZFJUxlbNeH0ODk6iz6fx-c7g7c91dJyId-rH1vrSv7HqngM7UpVsv9g2fVF8QDuo31xixbG7V_Z-KDQK0EuI95tWQ5XVKdgmwIcVmhg3BPlLNfD-be6wc_lTNbNVREsrK-qL3H-GhakGWqGJP8SraG8Ht2Lzud1Q0p0DK6XDdpTkop9QWIxpUnK7lfRXRRXrlZF5LN5XdE4age0gmQzlReJinZdhpIW8nKdYnEXQaRe29SGvCR5TtN3maftvfW2hYN6iYxPAuEWLk88FU497eYSytpXM4zhLbNfnEeMD1Wv44kTdBlyUvfbqWFFBRdFd4ETnJq_i1aQaF8dUW-kS0ivt06XaD_EjwLqurN9Dlj6Oph2ROfcrZL921TjWhh_LXWXSw65DrmJ-z9HYOalxQ9jP46-Yvjns9cagPtTAzZIJzSUH1NCqnU2wixMfUVolu5vexzb79pd4lrsZH2o0wfsfhv8wAdH8kO2o6tddmfayjt22T2XRAZXG_eI_fSAgwUcPOD7fbzhZrzB4Q2IN3R4A-ENhDfUBjbxBoc3OLxhA28gvKGH9x44uPcAOYZNtO2hNdrQof2YnR0enH48CtpVSAKFvngcmLEyQo1SgTOd5ImJcXDDsFqSqx2GkyTNo2isVRhTrJJn9D8nknMZ4Xc0EuPwCbtV4XM9Y6BUbGKhQikwUEp5MuHC5FoYwUnLHann7Kkzz8XctZq58IZ7ceOZl-xuh_krdtvg2KZfo6O8kG8sKr8AaQjLbA |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevated+serum+visfatin%2Fnicotinamide+phosphoribosyl-transferase+levels+are+associated+with+risk+of+postmenopausal+breast+cancer+independently+from+adiponectin%2C+leptin%2C+and+anthropometric+and+metabolic+parameters&rft.jtitle=Menopause+%28New+York%2C+N.Y.%29&rft.au=Dalamaga%2C+Maria&rft.au=Karmaniolas%2C+Konstantinos&rft.au=Papadavid%2C+Evangelia&rft.au=Pelekanos%2C+Nicolaos&rft.date=2011-11-01&rft.eissn=1530-0374&rft.volume=18&rft.issue=11&rft.spage=1198&rft_id=info:doi/10.1097%2Fgme.0b013e31821e21f5&rft_id=info%3Apmid%2F21712732&rft_id=info%3Apmid%2F21712732&rft.externalDocID=21712732 |